Global Epilepsy Market Research Report: by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), by Diagnosis & Treatment (Diagnosis & Treatment), by End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others), and Region - Forecast till 2023
The report presents a detailed analysis of Epilepsy Market by providing readers with a comprehensive overview of the market’s historical trajectory. The leading drivers and restraints affecting the global prostate cancer market are assessed in detail in the report. The historical impact of these drivers and restraints is analyzed in context of the current impact of these factors and projections are made for the likely impact of these drivers and restraints over the forecast period.
Major Key Players
To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch.
LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), and Abbott Laboratories (U.S.).
Segmentation Analysis
The global epilepsy market is segmented by condition, diagnosis & treatment, and end-user.
By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the epilepsy market.
By diagnosis & treatment, the treatment segment held 66.2% share of the epilepsy market in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.
By end-user, hospitals were the largest segment of the market with a valuation of USD 1,739.22 million in 2017. It is projected to exhibit a stellar 8.29% CAGR over the forecast period. On the other hand, clinics can showcase higher CAGR of 8.93% during the assessment period owing to clinics being a preferred center for diagnosis and treatment. In addition, adoption of latest equipment by doctors to provide excellent patient care can spur the growth of the segment.
Epilepsy Market report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report
Regional Analysis
Geographically, the global Epilepsy Market has been divided by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
Browse Full Report Page Enabled with complete Table of Content at https://www.marketresearchfuture.com/reports/epilepsy-market-7730
Chapters for This Epilepsy Market Study: -
Chapter 1: to describe Global Epilepsy Market Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2: to analyze the top manufacturers of Global Epilepsy Market, with sales, revenue, and price of Global Epilepsy Market.
Chapter 3: to display the competitive situation among the top manufacturers, with sales, revenue and market share in Forecasted Time.
Chapter 4: to show the Global Epilepsy Market by regions, with sales, revenue and market share of Global Epilepsy Market, for each region, during the forecast period.
Chapter 5, 6, 7, 8 and 9: to analyze the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 10: to show the market by type and application, with sales market share and growth rate by type, application, Methodology, Analyst Introduction, Data Source By MRFR
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
+1 646 845 9312 | Email: sales@marketresearchfuture.com
Epilepsy Market Research Report: By Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), By Diagnosis & Treatment (Diagnosis & Treatment), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Others) - Forecast till 2027Overview:Epilepsy can be classed as a major neurological disorder where the brain activity becomes abnormal and triggers unusual behavior and sensations.
The disorder is discernible in young children and young adults and requires proper attention in time before it can impact the body in an adverse way.The Global Epilepsy Market is showing a substantial market growth and its valuation can quite easily reach a valuation mark of USD 9,509.2 million by 2023, and it would also display 8.20% CAGR during the time period of 2018 and 2023, which as per the study of Market Research Future (MRFR) can be termed as forecast period.
The regional market is showing ample scope where a high prevalence of the disease can inspire growth in diverse regions.In addition, the global market would benefit from the presence of countries in the African region where various global bodies are trying to launch initiatives to assist local doctors in curbing the diseases.
However, poor economies can detract the growth rate.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7730 Segmentation:The report on the epilepsy market encompasses segments like by condition, diagnosis & treatment, and end-use to facilitate an easy understanding of the market and gauge well how the regional market would shape up in the coming years.By condition, the market report on epilepsy covers epilepsy drug-resistant/intractable epilepsy and others.
The treatment segment includes neurostimulation devices, anti-epileptic drugs, ketogenic diet, brain surgery, and others.
Cost-efficiency can be taken into consideration to understand market growth possibilities.By end-users, the epilepsy market can include clinics, hospitals, diagnostic centers, ambulatory surgical centers, and others.
(Albany, US) DelveInsight has launched a new report on Epilepsy MarketDelveInsight’s “Epilepsy- Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Epilepsy market report provides current treatment practices, emerging drugs, Epilepsy market share of the individual therapies, current and forecasted Epilepsy market Size from 2017 to 2030 segmented by seven major markets.
The Report also covers current Epilepsy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
View free sample page:- https://www.delveinsight.com/sample-request/epilepsy-marketView Report: https://www.delveinsight.com/report-store/epilepsy-marketEpilepsy MarketDelveInsight’s assessment based on the recent studies and data from registries shows that the EU5 countries and US accounts for the 30.34% and 51.41%, respectively, of the total prevalent cases out of all the Epilepsy cases in 7 major markets in 2017.
DelveInsight estimated the highest percentage of diagnosed prevalent populationof Epilepsy in the UK followed by Germany among the EU5 countries based on the recent studies and data from the registries of 2017.
View Report: https://www.delveinsight.com/report-store/epilepsy-marketEpilepsy Market OutlookThe Epilepsy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Epilepsy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
